Loading...
•
Sep 30, 2023
Amicus Therapeutics Q3 2023 Earnings Report
Amicus Therapeutics announced third quarter 2023 financial results, with total revenue of $103.5M, a 27% increase year-over-year and 22% at CER. Galafold® quarterly revenue surpassed $100M for the first time, and Pombiliti™ + Opfolda™ were approved and launched in the U.S., EU and U.K.
Key Takeaways
Amicus Therapeutics had a monumental quarter with the U.S. and U.K. approvals of Pombiliti and Opfolda, the global launches of Pombiliti and Opfolda, and the continued strong growth of Galafold worldwide. The company is on track to achieve all of its annual strategic priorities, including non-GAAP profitability in the fourth quarter.
Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER
Galafold® Quarterly Revenue Surpasses $100M for the First Time
Increasing FY 2023 Galafold® Revenue Growth Guidance to 16%-18% at CER
Pombiliti™ + Opfolda™ Approved and Launched in the U.S., EU and U.K.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.com Forward Guidance
Amicus is focused on the following five key strategic priorities in 2023